Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma

American Journal of Hematology

Volumn 83, Issue 9, 2008, Pages 697-701

  Katodritou, Eirini ^a,b   Verrou, Evgenia ^a,b   Hadjiaggelidou, Christina ^a   Gastari, Vassiliki ^a   Laschos, Konstantinos ^a   Kontovinis, Loukas ^a   Kapetanos, Dimitrios ^a   Constantinou, Nikos ^a   Terpos, Evangelos ^b   Zervas, Konstantinos ^a,b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b Greek Myeloma Study Group

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 MICROGLOBULIN; CREATININE; CYSTATIN C; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; VINCRISTINE;

ADULT; ADVERSE OUTCOME; AGE; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REMISSION; RISK FACTOR; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GREECE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 51449110543     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21239     Document Type: Article

References (28)

1. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
2. Siedenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-1214.
3. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
4. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-5972.
5. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
6. Wright JR, Yng YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25: 1027-1032.
7. Goldberg P. Danish researchers post long-awaited ARANESP results - ever so discreetly. Cancer Lett 2007;33:1-6.
8. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-4713.
9. Laugsch M, Metzen E, Svensson T, et al. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008;22:1005-1011.
10. Bohlius J, Wilson J, Seidelfeld J, et al. Recombinant human erythropoietin in cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.
11. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;27:914-924.
12. Rizzo JD, Somerfield MR, Hagerty KL, et al. American Society of Clinical Oncology/American Society of Hematology 2007. Clinical practice guideline update on the use of epoetin and darbepoetin. J Clin Oncol 2008;26:132-149.
13. Tefferi A. Pharmaceutical erythropoietin use in patients with cancer: Is it time to abandon ship or just drop anchor? Mayo Clin Proc 2007;82:1316-1318.
14. Khuri FR. Weighting the hazards of erythropoiesis stimulation in patients with cancer. N Eng J Med 2007;356:2445-2448.
15. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; DOI:10.1016
16. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008; DOI: 10.1002/cncr. 23505
17. Baz R, Walker E, Choueiri TK, et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 2007;117:162-167.
18. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-202 and iii-iv.
19. Steensma DP, Loprinzi CL. Erythropoietin use in cancer patients: A matter of life and death? J Clin Oncol 2005;23:5865-5868.
20. Crawford J. Erythropoietin: High profile, high scrutiny. J Clin Oncol 2007;25:1021-1023.
21. Katodritou E, Terpos E, Zervas K, et al. Hypochromic erythrocytes (%): A reliable marker of recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with multiple myeloma and lymphoma. Ann Hematol 2007;86;369-376.
22. Katodritou E, Zervas K, Terpos E, Brugnara C. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: The need for predictors and indicators of effectiveness has not abated. DOI:10.1111/j. 1365-2141.2008.07163.x
23. Kyle RA, Gertz MA, Witzig TE, et al. Mayo Clin Proc 2003;78:21-33.
24. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;20:3412-3420.
25. Weber D, Wang M, Delasalle K, Alexanian R. Confirmation of prognostic value of model using B2 microglobulin (B2M) and albumin for multiple myeloma (MM) proposed by the International Myeloma Working Group (IMWG) with similar results using B2M alone. Blood 2003;102(11):abstract.
26. Terpos E, Katodritou E, Kastritis E, et al. Greek Myeloma Study Group. Cystatin-C is a sensitive marker of renal impairment with an independent predictive value for survival in multiple myeloma: Reduction post bortezomib monotherapy. Blood 2007;110(11):abstract.
27. De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002;21:6848-6857.
28. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001;12:991-995.